Hormonal Contraception and Breast Cancer Risk

Nicole D White

doi:10.1177/1559827618754833

General Gynecology · Breast Health

Hormonal Contraception and Breast Cancer Risk

White ND

Published January 31, 2018 American journal of lifestyle medicine, 12(3), 224-226

DOI 10.1177/1559827618754833 PMID 30283254 PMC PMC6124967

Abstract

Contemporary hormonal contraception formulations contain lower doses of estrogen, have new synthetic progestin components, and provide novel methods of delivery that have not been studied extensively in relation to breast cancer risk. Given that hormonal contraception is the leading method of birth control in the United States, it is important to reevaluate risk using current formulations. Recent studies including contemporary hormonal contraception formulations will be described.

Topics

General Gynecology › Breast Health › Breast Cancer Risk · Contraception › Adverse Effects › Cardiovascular Effects · Therapeutics › Hormonal Agents › Progesterone and Progestins

Nicole D White

N White

PMID 30283254 30283254 DOI 10.1177/1559827618754833 10.1177/1559827618754833 White et al. 2018, White 2018

Hormonal Contraception and Breast Cancer Risk

Abstract

Topics

Related research

Contemporary Hormonal Contraception and the Risk of Breast Cancer

Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age

Oral contraceptive use and breast cancer: a prospective study of young women

Combined and progestagen-only hormonal contraceptives and breast cancer risk: A UK nested case-control study and meta-analysis